Replies to post #185060 on NorthWest Biotherapeutics Inc (NWBO)

[marzan]

Virgilio/Umibie, I too have the same feeling that the adjudicated 248 PFS and 233 OS events number count might not have reached yet because of overwhelming vaccine efficacy. If the 2018 Spring Data reflect the same, all LP has to call for is Interim Analysis and declare Efficacy. Because there is no point dragging the trial into indefinite future because the last few events are not happening displaying a possible Cure in these surviving patients.

[longfellow95]

Just to say that long tail survival is a measurement of efficacy for the secondary endpoint.

[Ultraz2]

I have to agree, if they failed OS, it is over. I can see PFS, but if OS not significant, I don’t see it being approved, and further trials would be necessary...perhaps at someone else’s expense, not Linda’s...company will “fail to be a going concern by year end.” But, unless she and others really benefited enough over the years to just turn around and throw a few million into a bad investment, I somehow just can’t fathom OS failing. 50/50...